Skip to main content
SpringerLink
Log in

Renal Denervation for Arrhythmias: Hope or Hype?

  • Invasive Electrophysiology and Pacing (J Singh, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Renal artery denervation (RDN) has been introduced as an ablation procedure that can effectively treat drug-resistant forms of hypertension. The ablative lesions reduce the afferent and efferent sympathetic nerve traffic to and from the kidneys, thus improving blood pressure control. Because of better control of blood pressure, and because the procedure reduces central sympathetic output to sensitive structures within the cardiovascular system, it has been hypothesized that RDN may be a valuable antiarrhythmic intervention. Preliminary results using RDN for atrial fibrillation control are promising. This review focuses on the mechanisms by which RDN may function as an antiarrhythmic treatment and early clinical results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82.

    PubMed  CAS  Google Scholar 

  2. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.

    PubMed  CAS  Google Scholar 

  3. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722–7.

    Article  PubMed  CAS  Google Scholar 

  4. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs; electrophysiological remodeling. Circulation. 1996;94:2953–60.

    Article  PubMed  CAS  Google Scholar 

  5. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197–204.

    Article  PubMed  CAS  Google Scholar 

  6. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101:2612–7.

    Article  PubMed  CAS  Google Scholar 

  7. Berkowitsch A, Neumann T, Kuniss M, et al. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder? PACE. 2010;33:1101–11.

    Article  PubMed  Google Scholar 

  8. Healy JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–9.

    Article  Google Scholar 

  9. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Eng J Med. 2009;360:1606–17.

    Article  Google Scholar 

  10. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560–5.

    Article  PubMed  Google Scholar 

  11. Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999–2005.

    Article  PubMed  Google Scholar 

  12. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570–8.

    Article  PubMed  CAS  Google Scholar 

  13. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–63.

    Article  PubMed  CAS  Google Scholar 

  14. Yang SS, Han W, Cao Y, et al. Effects of high thoracic epidural anesthesia on atrial electrophysiological characteristics and sympathetic nerve sprouting in a canine model of atrial fibrillation. Basic Res Cardiol. 2011;106:495–506.

    Article  PubMed  CAS  Google Scholar 

  15. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118:916–25.

    Article  PubMed  Google Scholar 

  16. Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100:1049–57.

    Article  PubMed  Google Scholar 

  17. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Eng J Med. 2009;361:932–4.

    Article  CAS  Google Scholar 

  18. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing of pulmonary veins by in vitro autonomic nerve stimulation. Hear Rhythm. 2005;2:624–31.

    Article  Google Scholar 

  19. Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Hear Rhythm. 2010;7:1282–90.

    Article  Google Scholar 

  20. Linz D, Mahfoud F, Schotten U, et al. Renal sympathetic denervation provide ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61:225–31.

    Article  PubMed  CAS  Google Scholar 

  21. Zhao Q, Yu S, Zou M, et al. Effects of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. JICE. 2012;35:119–25.

    Google Scholar 

  22. Linz D, Mahfoud F, Schotten U, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60:172–8.

    Article  PubMed  CAS  Google Scholar 

  23. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238:R353–8.

    PubMed  CAS  Google Scholar 

  24. Arrowood JA, Goureau JA, Minisi AJ, Davis AB, Mohanty PK. Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation. Circulation. 1995;92:402–8.

    Article  PubMed  CAS  Google Scholar 

  25. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690–7.

    Article  PubMed  CAS  Google Scholar 

  26. •• Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–70. This is the first study, performed as a prospective randomized trial, to demonstrate proof of principle that RDN may have clinical antiarrhythmic efficacy for AF.

    Article  PubMed  Google Scholar 

  27. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof of principle study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  28. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933–9.

    Article  PubMed  Google Scholar 

  29. • Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63–7. This is the first report of the potential value of RDN to treat refractory VT in patients.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Jonathan S. Steinberg has been a consultant for and has received grant support from Medtronic, St. Jude Medial, and Biosense-Webster.

Evgeny Pokushalov declares that he has no conflict of interest.

Suneet Mittal declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Arrhythmia Institute, Valley Health System, Columbia University College of Physicians & Surgeons, New York, NY, USA

    Jonathan S. Steinberg & Suneet Mittal

  2. Arrhythmia Institute, Valley Health System, Columbia University College of Physicians & Surgeons, Ridgewood, NJ, USA

    Jonathan S. Steinberg & Suneet Mittal

  3. State Research Institute of Circulation Pathology, Novosibirsk, Russia

    Evgeny Pokushalov

  4. 5 Columbus Circle, Suite 800, New York, NY, 10019, USA

    Jonathan S. Steinberg

Authors
  1. Jonathan S. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evgeny Pokushalov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suneet Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan S. Steinberg.

Additional information

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinberg, J.S., Pokushalov, E. & Mittal, S. Renal Denervation for Arrhythmias: Hope or Hype?. Curr Cardiol Rep 15, 392 (2013). https://doi.org/10.1007/s11886-013-0392-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-013-0392-0

Keywords

Search

Navigation